Collaboration with U.S. Army seeks to improve medic training and certification
Triage care on the battlefield requires split-second decision-making and proficiency in providing first aid. Correctly applying a tourniquet or inserting an intubation tube before a patient is evacuated to a hospital could save lives. To improve training for the field medics responsible for this level of care, researchers at Rensselaer Polytechnic Institute will team up with researchers from the United States Army Research Laboratory in Orlando, Florida, to better understand skill acquisition and to standardize the prolonged field care (PFC) certification process.
With the support of a $3.1 million grant from the U.S. Army Combat Capabilities Development Command Soldier Center, the team will combine neuroimaging, computer vision, eye-tracking, and artificial intelligence methods to make PFC certification faster, more objective, and scalable for all soldiers.
It's not just battle networks the military is looking to link together. A new request asks for prototypes for interoperability in medical data and networks.
News Category Global Banking & Finance Reviews
Philips, BioIntelliSense and University of Colorado receive U.S. Department of Defense funding for early COVID-19 detection
December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.
First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries
The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston (UTHealth).
The MATRICS-1 (MultiStem
® Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center.
According to the Centers for Disease Control (CDC), trauma is the leading cause of death for individuals under the age of 45 and the third leading cause of death in the U.S., accounting for approximately 180,000 fatalities each year. It is also a leading cause of serious disability, especially among young people and members of the military that suffer trauma.
December 22, 2020
Cambridge, MA –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
BioIntelliSense, Inc. [1], a continuous health monitoring and clinical intelligence company, today announced they have been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly USD 2.8 million from the U.S. Department of Defense (DoD) through a Medical Technology Enterprise Consortium (MTEC) award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal of the award is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases.